Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:8632 |
Name | Kaposi's sarcoma |
Definition | A connective tissue cancer that derives_from lymphatic endothelium, and derives_from spindle cells, results_in_formation_of vascular channels that fill with blood cells, has_material_basis_in Human herpesvirus 8 (HHV8). |
Source | DiseaseOntology.org |
Alt Ids | DOID:12776 DOID:12770 DOID:7239 DOID:12767 DOID:12778 DOID:12766 DOID:12777 DOID:12771 DOID:12762 DOID:6480 DOID:12761 DOID:12772 DOID:12768 DOID:12764 DOID:12775 DOID:8631 DOID:12774 |
Path | disease disease of cellular proliferation cancer organ system cancer musculoskeletal system cancer connective tissue cancer Kaposi's sarcoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00092222 | Phase II | Sirolimus Alpha 2 Interferon Cyclophosphamide + Doxorubicin + Etoposide + Prednisone + Vincristine Sulfate Rituximab Bortezomib Pegylated liposomal doxorubicin | Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity | Active, not recruiting | USA | 0 |
NCT00923936 | Phase II | Bevacizumab + Pegylated liposomal doxorubicin | Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma | Completed | USA | 0 |
NCT02137564 | Phase II | Nirogacestat | Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma | Withdrawn | 0 | |
NCT02408861 | Phase I | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors | Terminated | USA | AUS | 0 |
NCT02595866 | Phase I | Pembrolizumab | Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms | Completed | USA | 0 |
NCT03316274 | Phase I | Nivolumab | Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma | Completed | USA | 0 |
NCT03469804 | Phase II | Pembrolizumab | Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's Sarcoma (KAPKEY) | Unknown status | FRA | 0 |
NCT03915678 | Phase II | Atezolizumab + BDB001 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (AGADIR) | Recruiting | FRA | 0 |
NCT03993106 | Phase II | sEphB4-HSA | A Study of sEphB4-HSA in Kaposi Sarcoma | Recruiting | USA | 0 |
NCT04065152 | Phase II | Talimogene laherparepvec | Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma (KAPVEC) | Unknown status | FRA | 0 |
NCT04303117 | Phase Ib/II | NHS-IL12 Bintrafusp alfa + NHS-IL12 | NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma | Recruiting | USA | 0 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Active, not recruiting | USA | 0 |
NCT04893018 | Phase I | NT-I7 | NT-I7 for Kaposi Sarcoma in Patients With or Without HIV | Terminated | USA | 0 |
NCT04902443 | Phase I | Nivolumab + Pomalidomide | Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV | Recruiting | USA | 0 |
NCT04941274 | Phase Ib/II | Abemaciclib | Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma | Recruiting | USA | 0 |
NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | ISR | 0 |
NCT05329792 | Phase II | Daromun | L19IL2/L19TNF in Skin Cancer Patients | Recruiting | ITA | FRA | ESP | 0 |
NCT05859074 | Phase I | MQ710 + Pembrolizumab MQ710 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | Active, not recruiting | USA | 0 |
NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Recruiting | BRA | 0 |